Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6636438 | 1.00 | PPARG (0.58) | PPARGPPARA | |
| SCHEMBL2786676 | 0.92 | PPARG (0.66) | PPARGPPARA | |
| SCHEMBL6636646 | 0.92 | PPARG (0.66) | PPARGPPARA | |
| SCHEMBL6679623 | 0.89 | PPARG (0.61) | PPARGPPARA | |
| SCHEMBL6635105 | 0.89 | PPARG (0.61) | PPARGPPARA | |
| SCHEMBL6637185 | 0.88 | PPARG (0.58) | PPARGPPARA | |
| SCHEMBL7914564 | 0.83 | PPARG (0.70) | PPARGPPARA | |
| SCHEMBL2788918 | 0.82 | PPARG (0.62) | PPARGPPARA | |
| SCHEMBL6638351 | 0.82 | PPARG (0.62) | PPARGPPARA | |
| SCHEMBL2786254 | 0.82 | PPARG (0.55) | PPARGPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1414806-A1 | NOVEL VINYL N-(2-BENZOYLPHENYL)-L-TYROSINE DERIVATIVES AND THEIR USE AS ANTIDIABETICS ETC | NOVO NORDISK A/S (DK) | 2004-05-06 | — | — | EP | claimed |
| US-20030055076-A1 | Novel compounds, their preparation and use | NOVO NORDISK A/S (DK) | 2003-03-20 | — | — | US | claimed |
| WO-2003011834-A1 | NOVEL VINYL N-(2-BENZOYLPHENYL)-L-TYROSINE DERIVATIVES AND THEIR USE AS ANTIDIABETICS ETC | NOVO NORDISK A/S (DK) | 2003-02-13 | — | — | WO | claimed |
| US-20110300129-A1 | SYSTEMS AND METHODS FOR ENHANCING VACCINE EFFICACY | UNIVERSITY OF ROCHESTER (US) | 2011-12-08 | — | — | US | disclosed |
| WO-2010075037-A1 | SYSTEMS AND METHODS FOR ENHANCING VACCINE EFFICACY | UNIVERSITY OF ROCHESTER (US) | 2010-07-01 | — | — | WO | disclosed |
| EP-1414806-A1 | NOVEL VINYL N-(2-BENZOYLPHENYL)-L-TYROSINE DERIVATIVES AND THEIR USE AS ANTIDIABETICS ETC | NOVO NORDISK A/S (DK) | 2004-05-06 | — | — | EP | disclosed |
| US-20030055076-A1 | Novel compounds, their preparation and use | NOVO NORDISK A/S (DK) | 2003-03-20 | — | — | US | disclosed |
| WO-2003011834-A1 | NOVEL VINYL N-(2-BENZOYLPHENYL)-L-TYROSINE DERIVATIVES AND THEIR USE AS ANTIDIABETICS ETC | NOVO NORDISK A/S (DK) | 2003-02-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030055076-A1 | Novel compounds, their preparation and use | PPARG, PPARA, PPARD | PPARG 1/4885PPARA 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.